What is the share price of Nectar Lifesciences Ltd (NECLIFE) today?
The share price of NECLIFE as on 13th March 2025 is ₹23.79. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Nectar Lifesciences Ltd (NECLIFE) share?
The past returns of Nectar Lifesciences Ltd (NECLIFE) share are- Past 1 week: 0.84%
- Past 1 month: -16.29%
- Past 3 months: -32.10%
- Past 6 months: -53.54%
- Past 1 year: -24.55%
- Past 3 years: -10.54%
- Past 5 years: 183.05%
What are the peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE)?
The peers or stocks similar to Nectar Lifesciences Ltd (NECLIFE) include:What is the market cap of Nectar Lifesciences Ltd (NECLIFE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nectar Lifesciences Ltd (NECLIFE) is ₹561.77 Cr as of 13th March 2025.What is the 52 week high and low of Nectar Lifesciences Ltd (NECLIFE) share?
The 52-week high of Nectar Lifesciences Ltd (NECLIFE) is ₹56.50 and the 52-week low is ₹24.77.What is the PE and PB ratio of Nectar Lifesciences Ltd (NECLIFE) stock?
The P/E (price-to-earnings) ratio of Nectar Lifesciences Ltd (NECLIFE) is 112.58. The P/B (price-to-book) ratio is 0.53.Which sector does Nectar Lifesciences Ltd (NECLIFE) belong to?
Nectar Lifesciences Ltd (NECLIFE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Nectar Lifesciences Ltd (NECLIFE) shares?
You can directly buy Nectar Lifesciences Ltd (NECLIFE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Nectar Lifesciences Ltd
NECLIFENectar Lifesciences Ltd
NECLIFE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹561 cr, stock is ranked 1,662
High RiskStock is 4.04x as volatile as Nifty
23.795.03% (-1.26)
23.795.03% (-1.26)
Price Chart
High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
AvgCan be considered moderately valued vs the market
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 33.05 | 0.53 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 47.10 | 6.00 | 0.55% |
Forecast & Ratings
Detailed Forecast —
Forecast data is currently unavailable for this stockPrice
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.
Peers
Compare with peersSUNPHARMA
PE Ratio
42.01
1Y Return
5.84%
Buy Reco %
88.24
CIPLA
PE Ratio
28.50
1Y Return
0.78%
Buy Reco %
72.73
TORNTPHARM
PE Ratio
63.27
1Y Return
15.80%
Buy Reco %
68.00
DRREDDY
PE Ratio
16.51
1Y Return
12.32%
Buy Reco %
45.16
LUPIN
PE Ratio
46.90
1Y Return
19.48%
Buy Reco %
63.64
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Annual Normal View
Income Statement
Annual Normal View
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,681.46 | 1,666.37 | 1,882.29 | 2,788.91 | 2,370.70 | 1,547.08 | 1,680.15 | 1,566.85 | 1,698.66 | 1,687.04 | ||||||||||
Raw Materials | 1,198.70 | 1,145.85 | 1,417.32 | 2,268.13 | 1,862.83 | 1,052.82 | 1,207.32 | 1,200.84 | 1,242.45 | 1,507.40 | ||||||||||
| Power & Fuel Cost | 87.89 | 75.44 | 91.85 | 103.47 | 92.72 | 84.63 | 101.41 | 127.39 | 129.52 | |||||||||||
| Employee Cost | 78.38 | 75.54 | 74.65 | 76.54 | 78.19 | 70.59 | 71.91 | 75.14 | 81.71 | |||||||||||
| Selling & Administrative Expenses | 56.54 | 59.98 | 52.23 | 67.99 | 67.01 | 72.04 | 66.86 | 62.64 | 61.39 | |||||||||||
| Operating & Other expenses | 15.44 | 62.48 | 4.06 | 2.56 | 45.89 | 179.49 | 62.79 | 4.66 | 17.46 | |||||||||||
EBITDA | 244.51 | 247.08 | 242.18 | 270.22 | 224.06 | 87.51 | 169.86 | 96.18 | 166.13 | 179.64 | ||||||||||
| Depreciation/Amortization | 57.39 | 62.25 | 64.31 | 63.26 | 60.77 | 60.25 | 56.97 | 59.12 | 60.72 | 61.32 | ||||||||||
| PBIT | 187.12 | 184.83 | 177.87 | 206.96 | 163.29 | 27.26 | 112.89 | 37.06 | 105.41 | 118.32 | ||||||||||
| Interest & Other Items | 123.31 | 117.41 | 115.20 | 148.14 | 125.83 | 112.04 | 78.81 | 79.49 | 87.14 | 81.07 | ||||||||||
| PBT | 63.81 | 67.42 | 62.67 | 58.82 | 37.46 | -84.78 | 34.08 | -42.43 | 18.27 | 37.25 | ||||||||||
| Taxes & Other Items | 9.59 | 12.08 | 10.41 | 11.22 | 5.68 | -11.50 | 9.03 | -18.24 | 13.28 | 20.25 | ||||||||||
| Net Income | 54.22 | 55.34 | 52.26 | 47.60 | 31.78 | -73.28 | 25.05 | -24.19 | 4.99 | 17.00 | ||||||||||
| EPS | 2.42 | 2.47 | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | 0.76 | ||||||||||
| DPS | 0.10 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.04 | 0.02 | 0.02 | 0.02 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
FY 2015
Annual report
PDFFY 2016
Annual report
PDFFY 2017
Annual report
PDFFY 2018
Annual report
PDFFY 2019
Annual report
PDFFY 2020
Annual report
PDFFY 2021
Annual report
PDFFY 2022
Annual report
PDFFY 2023
Annual report
PDFFY 2024
Annual report
PDFPeers & Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Nectar Lifesciences Ltd | 112.58 | 0.53 | — |
| Sun Pharmaceutical Industries Ltd | 42.01 | 6.00 | 0.81% |
| Cipla Ltd | 28.50 | 4.38 | 0.89% |
| Torrent Pharmaceuticals Ltd | 63.27 | 15.29 | 0.90% |
Price Comparison
Compare NECLIFE with any stock or ETFCompare NECLIFE with any stock or ETF
NECLIFE
Shareholdings
Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 11.27%
High Pledged Promoter Holding
Lower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 8.40%
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 1.84%
Shareholding Pattern
Shareholding History
Foreign Institutions
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 11, 2020
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 11, 2020
Cash Dividend
Ex DateEx DateSep 19, 2019
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2019
Cash Dividend
Ex DateEx DateSep 19, 2018
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 19, 2018
Cash Dividend
Ex DateEx DateSep 20, 2017
Final
Final | Div/Share: ₹0.05
Dividend/Share
₹0.05
Ex DateEx Date
Sep 20, 2017
Cash Dividend
Ex DateEx DateSep 22, 2016
Final
Final | Div/Share: ₹0.10
Dividend/Share
₹0.10
Ex DateEx Date
Sep 22, 2016
News & Opinions
Articles & Videos
Spotlight
Nectar Lifesciences slumps after Mohali unit gets seven observations from EU authorities
In a regulatory filing made after market hours yesterday, the company stated that its API manufacturing facility in Saidpura, Mohali, Punjab, underwent a joint inspection by the European Directorate for the Quality of Medicines & HealthCare (EDQM) and the Spanish Agency of Medicines and Medical Devices (AEMPS) to assess compliance with EuGMP standards. Following the inspection, seven observations including four critical, were noted. Nectar Lifesciences said that it is in the process of preparing a corrective action and preventive action (CAPA) report to address the observations. The company emphasized its commitment to quality and compliance with cGMP standards. The European regulator will conduct a re-inspection of the facility to verify the compliance and CAPA submitted which may lead to EuGMP approval. Nectar Lifesciences is a research-based pharmaceutical company, primarily engaged in manufacturing APIs and formulation. The company has four manufacturing facilities across Punjab and Himachal Pradesh. The company is into manufacturing Cephalosporin (oral and sterile) at its two units in Derabassi and Punjab. The company's consolidated net profit surged to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in Q3 FY25 as compared with Q3 FY24. Powered by Capital Market - Live
1 day agoCapital Market - Live
Earnings
Nectar Lifescience consolidated net profit rises 399.36% in the December 2024 quarter
Net profit of Nectar Lifescience rose 399.36% to Rs 7.84 crore in the quarter ended December 2024 as against Rs 1.57 crore during the previous quarter ended December 2023. Sales rose 0.48% to Rs 454.33 crore in the quarter ended December 2024 as against Rs 452.16 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales454.33452.16 0 OPM %9.849.33 - PBDT28.1617.83 58 PBT12.552.46 410 NP7.841.57 399 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Nectar Lifescience announces board meeting date
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Nectar Lifescience consolidated net profit rises 449.02% in the September 2024 quarter
Net profit of Nectar Lifescience rose 449.02% to Rs 5.60 crore in the quarter ended September 2024 as against Rs 1.02 crore during the previous quarter ended September 2023. Sales rose 7.52% to Rs 427.88 crore in the quarter ended September 2024 as against Rs 397.96 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales427.88397.96 8 OPM %10.136.75 - PBDT24.2116.95 43 PBT8.671.64 429 NP5.601.02 449 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Nectar Lifescience schedules board meeting
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 November 2024Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Nectar Lifescience to conduct AGM
Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Nectar Lifescience to convene AGM
Nectar Lifescience announced that the Annual General Meeting (AGM) of the company will be held on 21 September 2024.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Nectar Lifescience consolidated net profit rises 63.19% in the June 2024 quarter
Net profit of Nectar Lifescience rose 63.19% to Rs 2.97 crore in the quarter ended June 2024 as against Rs 1.82 crore during the previous quarter ended June 2023. Sales declined 8.95% to Rs 358.85 crore in the quarter ended June 2024 as against Rs 394.12 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales358.85394.12 -9 OPM %11.099.02 - PBDT20.3818.39 11 PBT4.923.06 61 NP2.971.82 63 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Nectar Lifescience to conduct board meeting
Nectar Lifescience will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Nectar Lifesciences' Dinesh Dua Speaks On Impact Of ATD Levied On Key Products | Chartbusters
3 years agoCNBC-TV18
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -9.44%, vs industry avg of 9.04%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.27% to 0.45%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -36.31%, vs industry avg of 15.27%